Ovarian function during use of vaginal rings delivering three different doses of Nestorone®

Contraception

Volumn 63, Issue 5, 2001, Pages 257-261

  Brache, Vivian ^a   Mishell, Daniel R ^b   Lahteenmaki, Pekka ^c   Alvarez, Francisco ^a   Elomaa, Kaisa ^c   Jackanicz, Theodore ^d   Faundes, Anibal ^a  

^a PROFAMILIA   (Dominican Republic)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF HELSINKI   (Finland)

^d POPULATION COUNCIL   (United States)

Author keywords

Contraceptive rings; Luteal activity; Nestorone ; Ovarian function; Persistent follicles

Indexed keywords

ELASTOMER; ELCOMETRINE; ESTRADIOL; GESTAGEN; PROGESTERONE;

ADULT; ARTICLE; BLOOD ANALYSIS; CLINICAL TRIAL; CONTRACEPTION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; FEMALE; HORMONE BLOOD LEVEL; HUMAN; LUTEAL PHASE; NORMAL HUMAN; OVARY FOLLICLE; OVARY FUNCTION; OVULATION INHIBITION; RANDOMIZED CONTROLLED TRIAL; VAGINA RING;

ADMINISTRATION, INTRAVAGINAL; ADOLESCENT; ADULT; CONTRACEPTIVE AGENTS, FEMALE; CONTRACEPTIVE DEVICES, FEMALE; DRUG IMPLANTS; ESTRADIOL; FEMALE; HUMANS; NORPROGESTERONES; OVARY; PROGESTERONE;

EID: 0034975703     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0010-7824(01)00199-8     Document Type: Article

References (42)

1. Contraception by means of a Silastic vaginal ring impregnated with medroxyprogesterone acetate
2. Clinical performance and endocrine profiles with contraceptive vaginal rings containing a combination of estradiol and d-norgestrel
3. Bleeding and ovulation control with use of a small contraceptive vaginal ring releasing levonorgestrel and estradiol
4. A multicenter study of levonorgestrel-estradiol contraceptive vaginal rings. I. Use-effectiveness. An international comparative trial
5. Levonorgestrel and estradiol release from an improved contraceptive vaginal ring
6. Pharmacodynamics of a contraceptive vaginal ring releasing norethindrone and estradiol: Ovarian function, bleeding control and lipoprotein patterns
7. Fertility regulation in nursing women: VIII. Progesterone plasma levels and contraceptive efficacy of a progesterone-releasing vaginal ring
8. Pharmacodynamics of a contraceptive vaginal ring releasing 3-keto-desogestrel
9. Microdose intravaginal levonorgestrel contraception: A multicentre clinical trial. I. Contraceptive efficacy and side effects
10. Clinical performance and endocrine profiles of contraceptive vaginal rings releasing 3-keto-desogestrel and ethinylestradiol
11. Contraception with a vaginal ring releasing 3-keto-desogestrel and ethinylestradiol
12. Evaluation of four different contraceptive vaginal rings: Steroid serum levels, luteal activity, bleeding control and lipid profiles
13. Practical experience in the UK with an oestrogen/progestogen contraceptive vaginal ring
14. The effects of a combined contraceptive vaginal ring releasing ethinylestradiol and 3-ketodesogestrel on vaginal flora
15. Progesterone-releasing vaginal rings for use in postpartum contraception. II. Pharmacokinetic profiles in women
16. The 3-ketodesogestrel/ethinylestradiol ring: A new parenteral form of hormonal contraception
17. Contraceptive vaginal ring releasing norethindrone acetate and ethinyl estradiol
18. Dose-finding study of a contraceptive ring releasing norethindrone acetate/ethinyl estradiol
19. Fertility regulation in nursing women. IX. Contraceptive performance, duration of lactation, infant growth, and bleeding patterns during use of progesterone vaginal rings, progestin-only pills, Norplant implants, and Copper T 380-A intrauterine devices
20. Contraception for lactating women: A comparative trial of a progesterone-releasing vaginal ring and the Copper T 380A IUD
21. Effect of different insertion regimens on side effects with a combination contraceptive vaginal ring
22. A comparative study of two contraceptive vaginal rings releasing norethindrone acetate, and differing doses of ethinyl estradiol
23. Efficacy, bleeding patterns and side effects of a 1-year contraceptive vaginal ring
24. Preregistration study on the safety and contraceptive efficacy of a progesterone-releasing vaginal ring in Chilean nursing women
25. Acceptability of the contraceptive vaginal ring by rural and urban population in two Latin American countries
26. The acceptability of a combined oestrogen/progestogen contraceptive vaginal ring
27. Women's perceptions, and experience with the progesterone vaginal ring for contraception during breastfeeding
28. Nestorone®: A progestin with a unique pharmacological profile
29. Unaltered lipoprotein and carbohydrate metabolism during treatment with contraceptive subdermal implants containing ST-1435
30. Serum lipids, blood pressure, body weight, and serum chemistry in women using subcutaneous (s.c.) contraceptive releasing the progestin ST 1435
31. Fertility control with subdermal Silastic capsules containing a new progestin (ST-1435)
32. Contraception with s.c. capsules containing ST-1435. Pituitary and ovarian function and plasma levels of ST-1435
33. Pituitary and ovarian function during contraception with one s.c. implant releasing a progestin, ST-1435
34. A contraceptive subdermal implant releasing the progestin ST-1435: Ovarian function, bleeding patterns, and side effects
35. Contraception with subdermal implants releasing the progestin ST-1435: A dose-finding study
36. Clinical trial with Nestorone subdermal contraceptive implants
37. Ovarian function during use of Nestorone® subdermal implants
38. Pharmacokinetic and pharmacodynamic studies of vaginal rings releasing low-dose levonorgestrel
39. Pharmacokinetic and pharmacodynamic effects of vaginal rings releasing levonorgestrel at a rate of 27 micrograms/24 h: A pilot study
40. Norplant® consensus statement and background review
41. A multicenter study of levonorgestrel-estradiol contraceptive vaginal rings. III. Menstrual patterns. An international comparative trial
42. Clinical performance and endocrine profiles with contraceptive vaginal rings containing a combination of estradiol and d-norgestrel